Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last2,481 to 2,500 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Cycloset vs Placebo: Subjects Experiencing Serious Adverse Events | 176 of 2,054 98 of 1,016 | -1.1 points -3.4 to 1.0 | 3,070 | NCT00377676 Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes |
| Cycloset vs Placebo: serious adverse events | 176 of 2,054 98 of 1,016 | -1.1 points -3.4 to 1.0 | 3,070 | NCT00377676 Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes |
| Ginkgo Biloba vs Placebo: Number of Participants With Incident Dementia | 277 of 1,545 246 of 1,524 | 1.8 points -0.9 to 4.4 | 3,069 | NCT00010803 Ginkgo Biloba Prevention Trial in Older Individuals |
| Ginkgo Biloba vs Placebo: serious adverse events | 1,000 of 1,545 961 of 1,524 | 1.7 points -1.7 to 5.1 | 3,069 | NCT00010803 Ginkgo Biloba Prevention Trial in Older Individuals |
| NOMAC-E2 vs NETA-EE: Number of Participants Who Experience at Least One Venous or Arterial Thrombotic/Thromboembolic Event | 0 of 2,465 1 of 604 | -0.2 points -0.9 to 0.0 | 3,069 | NCT01656434 Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448) |
| NOMAC-E2 vs NETA-EE: serious adverse events | 20 of 2,465 8 of 604 | -0.5 points -1.8 to 0.3 | 3,069 | NCT01656434 Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448) |
| Best Practice Clinic-Based Care vs Telehealth Care: serious adverse events | 29 of 1,646 34 of 1,422 | -0.6 points -1.7 to 0.4 | 3,068 | NCT02996565 Pragmatic Trial Comparing Telehealth Care and Optimized Clinic-Based Care for Uncontrolled High Blood Pressure |
| Ferric Carboxymaltose vs Placebo: Number of Deaths | 131 of 1,532 158 of 1,533 | -1.8 points -3.8 to 0.3 | 3,065 | NCT03037931 Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study |
| Ferric Carboxymaltose vs Placebo: deaths from any cause | 354 of 1,532 367 of 1,533 | -0.8 points -3.8 to 2.2 | 3,065 | NCT03037931 Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study |
| Ferric Carboxymaltose vs Placebo: Number of Hospitalizations for Heart Failure | 297 of 1,532 332 of 1,533 | -2.3 points -5.1 to 0.6 | 3,065 | NCT03037931 Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study |
| Ferric Carboxymaltose vs Placebo: serious adverse events | 413 of 1,532 401 of 1,533 | 0.8 points -2.3 to 3.9 | 3,065 | NCT03037931 Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study |
| COPE participants vs Non-COPE participants: deaths from any cause | 8 of 173 92 of 2,885 | 1.4 points -0.9 to 5.7 | 3,058 | NCT03326206 Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program |
| COPE participants vs Non-COPE participants: serious adverse events | 2 of 173 3 of 2,885 | 1.1 points 0.2 to 4.0 | 3,058 | NCT03326206 Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program |
| Fluarix 50-64 Years Group vs Fluarix 65+ Years Group: deaths from any cause | 2 of 1,047 10 of 2,007 | -0.3 points -0.7 to 0.2 | 3,054 | NCT00377611 Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™ |
| Fluarix 50-64 Years Group vs Fluarix 65+ Years Group: serious adverse events | 23 of 1,047 105 of 2,007 | -3.0 points -4.3 to -1.6 | 3,054 | NCT00377611 Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™ |
| Phone Call Group (Intervention Arm) vs Usual Care Group (Control Arm): Mortality | 68 of 1,534 75 of 1,520 | -0.5 points -2.0 to 1.0 | 3,054 | NCT03050918 Discharge Follow-up Phone Call Program |
| Phone Call Group (Intervention Arm) vs Usual Care Group (Control Arm): deaths from any cause | 68 of 1,534 75 of 1,520 | -0.5 points -2.0 to 1.0 | 3,054 | NCT03050918 Discharge Follow-up Phone Call Program |
| Phone Call Group (Intervention Arm) vs Usual Care Group (Control Arm): Number of Participants With In-patient Re-admissions | 228 of 1,534 232 of 1,520 | -0.4 points -2.9 to 2.1 | 3,054 | NCT03050918 Discharge Follow-up Phone Call Program |
| Enhanced Treatment vs Current Practice: Number of Children With Fever Who Received Coartem (Artemether-lumefantrine) | 265 of 963 2,066 of 2,084 | -71.6 points -74.4 to -68.7 | 3,047 | NCT00513500 Zambia Integrated Management of Malaria and Pneumonia Study |
| Rivaroxaban 2.5 mg Twice Daily (BID) vs Acetylsalicylic Acid 100 mg Once Daily (OD): Number of Participants With Non Coronary Artery Bypass Graft-Related (Non CABG-related) Thrombolysis in Myocardial Infarction (TIMI) Clinically Significant Bleeding Events | 80 of 1,519 74 of 1,518 | 0.4 points -1.2 to 2.0 | 3,037 | NCT02293395 A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome |
Code
curl "https://conductscience.org/api/comparisons/v1?page=125"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=125
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT00377676-0dfac83e",
"title": "Cycloset vs Placebo: Subjects Experiencing Serious Adverse Events",
"summary": "176 of 2054 against 98 of 1016; risk difference -1.1 points, 95% interval -3.4 to 1.0; NCT00377676, Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes",
"record": "/library/comparisons/NCT00377676-0dfac83e",
"nct_id": "NCT00377676",
"kind": "outcome",
"participants": 3070,
"risk_difference": {
"value": -0.010770227480084951,
"lower": -0.03350515068102344,
"upper": 0.010296708659199474
},
"group_1": "176 of 2,054",
"group_2": "98 of 1,016",
"difference": "-1.1 points",
"interval": "-3.4 to 1.0",
"trial_title": "Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes"
},
{
"id": "NCT00377676-sae",
"title": "Cycloset vs Placebo: serious adverse events",
"summary": "176 of 2054 against 98 of 1016; risk difference -1.1 points, 95% interval -3.4 to 1.0; NCT00377676, Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes",
"record": "/library/comparisons/NCT00377676-sae",
"nct_id": "NCT00377676",
"kind": "serious-adverse-events",
"participants": 3070,
"risk_difference": {
"value": -0.010770227480084951,
"lower": -0.03350515068102344,
"upper": 0.010296708659199474
},
"group_1": "176 of 2,054",
"group_2": "98 of 1,016",
"difference": "-1.1 points",
"interval": "-3.4 to 1.0",
"trial_title": "Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=126",
"request_id": "jifxY_rBVMp5oBZA"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant